high risk head and neck cancers better with nivolumab adjuvant added to SOC
Interviews and expert commentary tagged “high risk head and neck cancers better with nivolumab adjuvant added to SOC” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers
“Adjuvant nivolumab added to chemoradiotherapy after surgery provided a statistically and clinically meaningful disease-free survival improvement in PD-L1 all-comers patients. This is the first time i
3 July 2025
10:00